Literature DB >> 6303992

Radioprotection of two mouse tumors by WR-2721 in single and fractionated treatments.

F A Stewart, A Rojas, J Denekamp.   

Abstract

The radioprotective effect of WR-2721 has been studied in two murine tumors using single doses or five daily fractions. Single dose irradiations of the SA FA resulted in a highly variable radio-protective response. In one experiment large protection factors (1.2-2.5) were obtained, with the greatest protection at low X ray doses. In later experiments with the same tumor, there was little or no radioprotection. The Ca MT was significantly protected against single dose irradiation with both 250 mg/kg and 400 mg/kg of the drug. In a five fraction schedule the extent of radioprotection for CA MT was greater than with single X ray doses for the same drug dose per fraction. Tumor protection factors from the present work and from the literature are compared with published protection factors for normal tissues. Significant tumor radioprotection is seen in most studies. The data indicate more variability in the extent of tumor protection for a given drug dose than is seen in normal tissues. Tumor protection is often greatest at low X ray doses which may be a result of preferential protection of the better-oxygenated tumor cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6303992     DOI: 10.1016/0360-3016(83)90069-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

Review 1.  Modifiers of radiosensitivity.

Authors:  A Rojas; J Denekamp
Journal:  Experientia       Date:  1989-01-15

Review 2.  Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.

Authors:  C R Culy; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.

Authors:  Nicole L Simone; Cynthia Ménard; Benjamin P Soule; Paul S Albert; Peter Guion; Sharon Smith; Denise Godette; Nancy S Crouse; Linda C Sciuto; Theresa Cooley-Zgela; Kevin Camphausen; C Norman Coleman; Anurag K Singh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-12       Impact factor: 7.038

Review 4.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.